GBT - Global Blood Therapeutics, Inc.
| Previous Close | 58.08 |
| Open | 58.45 |
| Bid | 58.00 x 1800 |
| Ask | 61.25 x 1200 |
| Day's Range | 58.23 - 60.79 |
| 52 Week Range | 30.15 - 62.50 |
| Volume | 467,877 |
| Avg. Volume | 660,435 |
| Market Cap | 3.38B |
| Beta (3Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.41 |
| Earnings Date | Jul 31, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 89.08 |
- GlobeNewswire•9 days ago
GBT Announces Upcoming Data Presentations at 24th European Hematology Association (EHA) Congress Supporting Voxelotor Sickle Cell Disease Program
Phase 3 HOPE Study 24-Week Efficacy Results from Full Patient Cohort to be Presented During Presidential Symposium New Drug Application (NDA) Submission Planned for Voxelotor.
- Zacks•15 days ago
Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1
Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.
- Associated Press•17 days ago
Global Blood: 1Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 87 cents per share. The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment ...
- GlobeNewswire•17 days ago
GBT Reports Recent Business Progress and First Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., May 08, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the first.
- Simply Wall St.•17 days ago
When Will Global Blood Therapeutics, Inc. (NASDAQ:GBT) Breakeven?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Global Blood Therapeutics, Inc.'s (NASDAQ:GBT): Global Blood Therapeutics, Inc., a clinical-sta...
- GlobeNewswire•19 days ago
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., May 06, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on May 1, 2019, the compensation committee of GBT’s board.
- Insider Monkey•25 days ago
Did Hedge Funds Drop The Ball On Global Blood Therapeutics Inc (GBT) ?
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
- GlobeNewswire•2 months ago
GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., April 02, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life.
- Simply Wall St.•3 months ago
Announcing: Global Blood Therapeutics (NASDAQ:GBT) Stock Increased An Energizing 211% In The Last Three Years
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can make much more than 100% if theRead More...
- GlobeNewswire•3 months ago
Detailed Research: Economic Perspectives on Intelsat S.A, Sprint, Restaurant Brands International, Tower Semiconductor, TE Connectivity, and Global Blood Therapeutics — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- GlobeNewswire•3 months ago
GBT Announces Participation at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 04, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the Cowen and Company 39th Annual.
- American City Business Journals•3 months ago
Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million
The startup is tapping a wealth of genetic information in databases and a new wave of technology in its quest to figure out why some people with a genetic mutation can have a more-severe form of a disease than others with the same mutation.
- GlobeNewswire•3 months ago
GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the fourth.
- GlobeNewswire•3 months ago
GBT Announces Participation at the 8th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 8th Annual SVB Leerink Global.
- GlobeNewswire•3 months ago
GBT Launches ACCEL Grants Program to Improve Access to Care for People with Sickle Cell Disease
—The Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) Supports Novel Projects Aimed at Improving Access to High-Quality Healthcare for People with Sickle.
- Motley Fool•4 months ago
Why Global Blood Therapeutics Surged 16.7% Higher in January
Investors hope that its lead drug candidate can make it to the Food and Drug Administration for approval soon.
- Motley Fool•4 months ago
6 Biotech Stocks to Watch Now
Here are six stocks that could pop or drop in 2019 based on these fast-approaching catalysts.
- GlobeNewswire•4 months ago
GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced that data from its Phase 1/2 study of voxelotor in patients with sickle cell disease (SCD) were published online in Blood, a peer-reviewed publication of the American Society of Hematology. GBT intends to submit a New Drug Application (NDA) for voxelotor under an accelerated approval pathway to the U.S. Food and Drug Administration (FDA) later this year.
- Motley Fool•4 months ago
Should You Sell CRISPR Therapeutics Following an Analyst Downgrade?
Citigroup has downgraded the gene-editing pioneer to "sell," but Wall Street has been known to make mistakes.
- GlobeNewswire•5 months ago
GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 37th Annual J.P. Morgan Healthcare.
- GlobeNewswire•5 months ago
GBT Appoints Dawn Svoronos to Board of Directors
Global Blood Therapeutics, Inc. (GBT) (GBT) today announced the appointment of Dawn Svoronos to the company’s board of directors. Ms. Svoronos has more than 30 years of experience in the biopharmaceutical industry in the United States, Canada, Europe and Asia, including a nearly 25-year tenure at Merck & Co. “Dawn is a global biopharmaceutical leader whose addition to the board will strengthen the existing breadth of talent,” said Ted W. Love, M.D., president and chief executive officer of GBT.
